<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Patient Prefer Adherence</journal-id><journal-id journal-id-type="iso-abbrev">Patient Prefer Adherence</journal-id><journal-title-group><journal-title>Patient preference and adherence</journal-title></journal-title-group><issn pub-type="epub">1177-889X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23271897</article-id><article-id pub-id-type="pmc">3526885</article-id><article-id pub-id-type="doi">10.2147/PPA.S38897</article-id><article-id pub-id-type="publisher-id">ppa-6-887</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nachega</surname><given-names>Jean B</given-names></name><xref ref-type="aff" rid="af1-ppa-6-887">1</xref><xref ref-type="aff" rid="af2-ppa-6-887">2</xref><xref ref-type="aff" rid="af4-ppa-6-887">4</xref><xref ref-type="corresp" rid="c1-ppa-6-887"/></contrib><contrib contrib-type="author"><name><surname>Morroni</surname><given-names>Chelsea</given-names></name><xref ref-type="aff" rid="af1-ppa-6-887">1</xref></contrib><contrib contrib-type="author"><name><surname>Chaisson</surname><given-names>Richard E</given-names></name><xref ref-type="aff" rid="af2-ppa-6-887">2</xref><xref ref-type="aff" rid="af3-ppa-6-887">3</xref><xref ref-type="aff" rid="af4-ppa-6-887">4</xref></contrib><contrib contrib-type="author"><name><surname>Goliath</surname><given-names>Rene</given-names></name><xref ref-type="aff" rid="af1-ppa-6-887">1</xref></contrib><contrib contrib-type="author"><name><surname>Efron</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="af4-ppa-6-887">4</xref></contrib><contrib contrib-type="author"><name><surname>Ram</surname><given-names>Malathi</given-names></name><xref ref-type="aff" rid="af2-ppa-6-887">2</xref></contrib><contrib contrib-type="author"><name><surname>Maartens</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="af1-ppa-6-887">1</xref></contrib></contrib-group><aff id="af1-ppa-6-887"><label>1</label>University of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa</aff><aff id="af2-ppa-6-887"><label>2</label>Johns Hopkins University, Bloomberg School of Public Health, Departments of International Health and Epidemiology, Baltimore, Maryland, USA</aff><aff id="af3-ppa-6-887"><label>3</label>Johns Hopkins University, School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA</aff><aff id="af4-ppa-6-887"><label>4</label>Johns Hopkins University, Center for Tuberculosis Research, Baltimore, Maryland, USA</aff><author-notes><corresp id="c1-ppa-6-887">Correspondence: Jean B Nachega, Johns Hopkins University, Bloomberg School of Public Health, Department of International Health, Global Disease Epidemiology and Control Program, 615 N Wolfe Street, Suite W5031, Baltimore, MD 21205, USA, Tel +1 410 955 2378, Fax +1 410 502 6733, Email <email>jnachega@jhsph.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2012</year></pub-date><volume>6</volume><fpage>887</fpage><lpage>891</lpage><permissions><copyright-statement>&#x000a9; 2012 Nachega et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>We determined the impact of immune reconstitution inflammatory syndrome (IRIS) on antiretroviral therapy (ART) adherence in a cohort of 274 human immunodeficiency virus (HIV)-infected South African adults initiating ART.</p></sec><sec><title>Methods</title><p>We carried out a secondary analysis of data from a randomized controlled trial of partially supervised ART in Cape Town, South Africa. Monthly pill count adherence, viral suppression (HIV viral load &#x0003c; 50 c/mL), and IRIS events were documented. Poisson regression was used to identify variables associated with ART adherence below the median in the first 6 months of ART.</p></sec><sec><title>Results</title><p>We enrolled 274 patients: 58% women, median age 34 years, median CD4 count 98 cells/&#x003bc;L, 46% World Health Organization clinical stage IV, and 40% on treatment for tuberculosis (TB). IRIS and TB-IRIS developed in 8.4% and 6.6% of patients, respectively. The median cumulative adherence at 6 months for those with an IRIS event vs no IRIS was 95.5% vs 98.2% (<italic>P</italic> = 0.04). Although not statistically significant, patients developing IRIS had a lower 6-month viral load suppression than those without IRIS (68% vs 80%, <italic>P</italic> = 0.32). ART adherence below the median of 98% was independently associated with alcohol abuse (relative risk [RR] 1.5; 95% confidence interval [CI] 1.2&#x02013;1.9; <italic>P</italic> = 0.003) and IRIS events (RR 1.7; 95% CI 1.2&#x02013;2.2; <italic>P</italic> = 0.001).</p></sec><sec><title>Conclusion</title><p>Although IRIS events were associated with slightly lower adherence rates, overall adherence to ART remained high in this study population. Concerns about IRIS should not deter clinicians from early ART initiation.</p></sec></abstract><kwd-group><kwd>ART</kwd><kwd>adherence</kwd><kwd>TB</kwd><kwd>HIV/AIDS</kwd><kwd>IRIS</kwd></kwd-group></article-meta></front><body><p>Antiretroviral therapy (ART) improves outcomes of human immunodeficiency virus (HIV)-related tuberculosis (TB),<xref ref-type="bibr" rid="b1-ppa-6-887">1</xref>,<xref ref-type="bibr" rid="b2-ppa-6-887">2</xref> and results from the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT), Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA), and The AIDS Clinical Trial Group (ACTG) Study 5221 (STRIDE) randomized controlled trials showed that early ART initiation (within the first 2 months of anti-TB therapy) is associated with lower morbidity and mortality in TB-HIV co-infected patients, despite being associated with a two to threefold increase in immune reconstitution inflammatory syndrome (IRIS) events.<xref ref-type="bibr" rid="b3-ppa-6-887">3</xref>&#x02013;<xref ref-type="bibr" rid="b5-ppa-6-887">5</xref> Whether IRIS events related to TB or other diseases affect ART adherence is largely unknown.</p><p>We measured the frequency and timing of IRIS events in a cohort of HIV-infected South African adults initiating ART and measured the association of these events with subsequent ART adherence.</p><sec sec-type="methods"><title>Methods</title><sec sec-type="methods"><title>Study design, setting, and patient enrollment</title><p>This was a secondary analysis of a randomized controlled trial evaluating the impact of patient-nominated treatment supporters with partial directly observed administration of ART (DOT-ART) on ART adherence, HIV viral load, and CD4+ T-cell count. This trial, which was reported in detail elsewhere,<xref ref-type="bibr" rid="b6-ppa-6-887">6</xref> showed that the presence of a patient-nominated supporter was not associated with improved ART adherence or virologic suppression but was associated with increased survival (a secondary endpoint).</p><p>The study was conducted at GF Jooste Hospital, Cape Town, South Africa, a public sector, secondary-level, peri-urban hospital with more than 12,000 admissions annually, about 20% of which are for infectious diseases (61% HIV). Government-funded comprehensive ART care is provided free of charge at primary care clinics and in the hospital clinic.</p><p>Eligibility criteria in the parent study were: (1) male or nonpregnant female 18 years of age or older; (2) HIV infection documented by two serologic tests; (3) eligible to start ART according to South African guidelines at the time<xref ref-type="bibr" rid="b8-ppa-6-887">8</xref> CD4+ T-cell count &#x02264; 200 cells/&#x003bc;L or World Health Organization clinical stage IV disease; (4) living in the study catchment area; and (5) willing to disclose HIV status to a treatment supporter. Patients were excluded if they had: (1) prior ART use; (2) life expectancy less than 6 months; (3) Karnofsky Performance Score<xref ref-type="bibr" rid="b9-ppa-6-887">9</xref> less than 60; (4) transaminases more than five times the upper limit of normal; or (5) history of single-dose nevirapine for prevention of mother to child transmission of HIV infection.</p></sec><sec><title>Antiretroviral therapy and anti-tuberculosis regimens</title><p>Standard first-line anti-TB treatment regimen was given per South African TB guidelines,<xref ref-type="bibr" rid="b8-ppa-6-887">8</xref> administered 5 days per week, and directly observed during the 2-month intensive phase. The initial ART regimen consisted of stavudine, lamivudine, and efavirenz.<xref ref-type="bibr" rid="b7-ppa-6-887">7</xref> For women not willing to use contraception, nevirapine was substituted for efavirenz. Regimen changes were permitted following South African HIV guidelines.<xref ref-type="bibr" rid="b7-ppa-6-887">7</xref> All patients were followed monthly for clinical evaluation, pill counts, and ART adherence counseling as needed.</p></sec><sec><title>Immune reconstitution inflammatory syndrome case definition</title><p>We retrospectively applied standardized definitions for tuberculosis and cryptococcal-associated IRIS, which have been proposed by the International Network for the Study of HIV-Associated IRIS (INSHI), for use in resource-limited settings.<xref ref-type="bibr" rid="b10-ppa-6-887">10</xref>,<xref ref-type="bibr" rid="b11-ppa-6-887">11</xref> Other events, such as herpes zoster virus (HZV) or herpes simplex virus (HSV), were considered as IRIS if they appeared within 3 months of ART initiation and had documented decreased viral load and/or immune reconstitution as evidenced by CD4+ T-cell count as per previously published reports.<xref ref-type="bibr" rid="b12-ppa-6-887">12</xref></p></sec><sec><title>Regulatory approvals</title><p>The study was approved by the committees on the Protection of Human Individuals or Research Ethics Boards from Johns Hopkins University School of Medicine, Baltimore, Maryland, and the University of Cape Town, Cape Town, South Africa.</p></sec><sec sec-type="methods"><title>Data analysis</title><p>We measured the proportions of patients with any IRIS and TB-IRIS events during the first 6 months of follow-up. We calculated ART adherence as the median cumulative monthly pill count over the same time period. Chi-square tests and Wilcoxon rank sum tests were used for comparisons of proportions and medians, as appropriate. We used log-binomial regression for both univariate and multivariate regression; this was followed by Poisson regression with robust variance estimation since the log-binomial model failed to converge. Our rationale for not using a logistic regression method is that odds ratios are likely to be biased (inflated) estimates of the relative risk, and thus misleading, when the outcome is common. Variables were included in the multivariate model if they were associated with adherence or IRIS events in univariate analysis (<italic>P</italic> &#x02264; 0.2). Associations with adherence were considered statistically significant in the multivariate regression model if <italic>P</italic> &#x02264; 0.05. Baseline alcohol abuse was evaluated by the validated, short, four-question, Cut down, Annoyed by criticism, Guilty about drinking, Eye-opener drinks (CAGE) screening questionnaire that diagnoses alcohol problems over a lifetime. A total score of two or higher (answering &#x0201c;yes&#x0201d; to two or more questions) indicates a problem with alcohol.<xref ref-type="bibr" rid="b13-ppa-6-887">13</xref> Data analysis was performed using STATA 11 (Stata Corporation, College Station, TX, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro"><title>Baseline characteristics and frequency of IRIS events</title><p>The baseline characteristics of patients with and without IRIS events are shown in <xref ref-type="table" rid="t1-ppa-6-887">Table 1</xref>. Overall, patients had advanced HIV disease, with 46% having AIDS and a median CD4+ T-cell count of 98 cells/&#x003bc;L (Interquartile range [IQR] 93&#x02013;148). Twenty-three patients out of 274 (8.4%) experienced an IRIS event (one patient with genital HSV&#x02212; and TB-IRIS, one with HZV-IRIS, three with paradoxical cryptococcal meningitis-IRIS, and 18 with TB-IRIS, which included 14 paradoxical TB-IRIS cases and four unmasking TB-IRIS cases). Overall, 6.6% of patients (n = 18) developed any TB-IRIS, and 9.8% of patients on TB treatment at ART initiation (11 of 112) developed paradoxical TB-IRIS. The median (IQR) time to any IRIS event from ART initiation was 15 days (7&#x02013;42), to any TB-IRIS was 14 days (6&#x02013;24.5), and to paradoxical TB-IRIS in those on TB treatment at ART initiation was 9 days (3&#x02013;18). In univariate analysis, IRIS events were associated with a nonsignificant lower baseline median (IQR) CD4+ T-cell count (78 [37&#x02013;112] vs 99 [45&#x02013;150]; <italic>P</italic> = 0.09) and earlier ART initiation after commencing TB treatment (proportion initiating ART within 2 months of starting TB chemotherapy 0.83 vs 0.58; <italic>P</italic> = 0.09). IRIS events were not associated with type of non-nucleoside reverse transcriptase inhibitor (8.1% of those on efavirenz versus 8.9% of those on nevirapine experienced an IRIS event; <italic>P</italic> = 0.9).</p></sec><sec><title>ART adherence, immunologic, virologic, and clinical outcomes</title><p>The median (IQR) cumulative pill count adherence at 6 months for those with an IRIS event was 95.5% (91.4&#x02013;97.8) vs 98.2% (94.6&#x02013;99.5) for those with no IRIS (<italic>P</italic> = 0.04). Seventy-eight percent of patients with an IRIS event had 6-month adherence below the median adherence of 98% compared to 44% of those without an IRIS event (<italic>P</italic> = 0.006). Median absolute change in CD4+ T-cell count (IQR) from baseline to 6 months in those with and without an IRIS event was an increase of 130 (44&#x02013;222) and 134 (58&#x02013;217) cells/&#x003bc;L, respectively (<italic>P</italic> = 0.98). Eighty percent of patients without an IRIS event compared with 68% of those with an IRIS event had an HIV viral load &#x0003c; 50 c/mL at 6 months (relative risk [RR] 0.85, 95% confidence interval [CI] 0.62&#x02013;1.16; <italic>P</italic> = 0.32). There were five hospital admissions (all TB-IRIS cases), but no documented fatal outcomes related to any of the IRIS events. In a multivariate Poisson regression model, alcohol abuse (RR 1.5, 95% CI 1.2&#x02013;1.9; <italic>P</italic> = 0.003) and having any IRIS event (RR 1.7, 95% CI 1.2&#x02013;2.2; <italic>P</italic> = 0.001) were independently and significantly associated with ART adherence below the median of 98% (<xref ref-type="table" rid="t2-ppa-6-887">Table 2</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study of South African adults initiating ART, we found that 6-month adherence rates were high (median 98%) but that having an IRIS event was associated with moderately lower adherence (median 95%). Although this observed difference in median ART adherence is unlikely to be of any clinical significance, it is worth noting that patients with IRIS events also experienced poorer virologic suppression at 6 months, although the difference was not statistically significant, raising the possibility of low statistical power to account for such nonsignificance. IRIS events may reduce ART adherence either because of the resulting morbidity or the erosion of patient confidence in the efficacy of ART.</p><p>ART adherence rates observed in this trial are similar to those in the SAPIT trial (97%),<xref ref-type="bibr" rid="b3-ppa-6-887">3</xref> suggesting that the high pill burden necessary to treat both HIV and TB does not affect ART adherence. However, ART adherence stratified by IRIS status was not reported in SAPIT, leaving open the question of whether IRIS events (rather than pill burden) might be associated with lower mortality. No ART adherence data were reported from the CAMELIA and STRIDE trials. In these three trials, similar proportions of viral suppression at 24 weeks were achieved among study participants in the earlier ART initiation group versus participants for whom ART was delayed after the initiation of TB treatment. This suggests that ART nonadherence events did not have a significant impact on virologic outcomes; however, virologic data stratified by IRIS events were not reported.<xref ref-type="bibr" rid="b3-ppa-6-887">3</xref>&#x02013;<xref ref-type="bibr" rid="b5-ppa-6-887">5</xref></p><p>Most of the IRIS events in this study were of minor or moderate morbidity and mortality, in agreement with other previously published reports.<xref ref-type="bibr" rid="b14-ppa-6-887">14</xref>&#x02013;<xref ref-type="bibr" rid="b16-ppa-6-887">16</xref> Five of the 18 TB-IRIS cases were admitted to hospital for an average of 1 week, and there were no fatal outcomes related to any of the IRIS events. Of note, if ART was discontinued at home, it was re-administrated during inpatient stay from patient&#x02019;s original ART stock. Therefore, it is unlikely that hospital admissions of these few IRIS cases could have a significant impact on the pill count adherence data.</p><p>Given the clear mortality benefit to early ART initiation in TB-HIV co-infected patients and the overall high rates of adherence seen both here and in SAPIT, concern about nonadherence to ART due to IRIS events should not deter clinicians from early ART initiation. Rather, patients experiencing IRIS events may be appropriate targets for additional ART adherence support in the first 6 months after ART initiation. It is important that clinicians counsel patients starting ART beforehand on the possibility that an IRIS event may occur and that it should not be viewed as a failure of ART and/or TB treatment. There is also a need for further research to evaluate interventions to prevent TB-IRIS in high TB-HIV endemic settings.<xref ref-type="bibr" rid="b17-ppa-6-887">17</xref></p><p>While informative, limitations of this study are the relatively small number of IRIS events and as a consequence a limited statistical power to detect significance for some of our findings. Therefore, future research that includes larger IRIS events should be undertaken to confirm our findings. In addition, the high overall rates of adherence and limited number of IRIS events limited our ability to consider other meaningful ART adherence cut points (eg, 80%, 90%). Finally, the sensitivity of pill count to detect nonadherence could be questioned. However, to date there are no established gold standard tools to monitor adherence since each measurement method has its own strengths and weaknesses.<xref ref-type="bibr" rid="b18-ppa-6-887">18</xref></p></sec><sec><title>Conclusion</title><p>ART adherence was excellent (.95%) in this study, regardless of whether IRIS events occurred. Thus, concerns about IRIS should not deter clinicians from early ART initiation, but close ART adherence monitoring is warranted as for any HIV-infected patient, irrespective of an IRIS event.</p></sec></body><back><ack><title>Acknowledgments</title><p>This paper was in part presented as a poster at the 19th Conference on Retroviruses and Opportunistic Infections, March 5&#x02013;9, 2012, Seattle, WA, USA, Abstract #941. We also acknowledge the immeasurable efforts of our study nurses, doctors, counselors, administrators, visiting residents, ID fellows, MHS student interns at the GF Jooste Hospital, Manenberg, Cape Town, South Africa. This work was partially supported by the National Institute of Allergy and Infectious Diseases, United States National Institutes of Health, R01 AI 5535901 (REC) and K23 068582-01 (JBN).</p></ack><fn-group><fn id="fn1-ppa-6-887"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ppa-6-887"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badri</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>Wood</surname><given-names>R</given-names></name></person-group><article-title>Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>2059</fpage><lpage>2064</lpage><pub-id pub-id-type="pmid">12086758</pub-id></element-citation></ref><ref id="b2-ppa-6-887"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Jamal</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995&#x02013;2001</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e826</fpage><pub-id pub-id-type="pmid">17786198</pub-id></element-citation></ref><ref id="b3-ppa-6-887"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdool Karim</surname><given-names>SS</given-names></name><name><surname>Naidoo</surname><given-names>K</given-names></name><name><surname>Grobler</surname><given-names>A</given-names></name><name><surname>Padayatchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Timing of initiation of antiretroviral drugs during tuberculosis therapy</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>8</issue><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">20181971</pub-id></element-citation></ref><ref id="b4-ppa-6-887"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanc</surname><given-names>FX</given-names></name><name><surname>Sok</surname><given-names>T</given-names></name><name><surname>Laureillard</surname><given-names>D</given-names></name><etal/></person-group><collab>CAMELIA (ANRS 1295&#x02013;CIPRA KH001) Study Team</collab><article-title>Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>16</issue><fpage>1471</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">22010913</pub-id></element-citation></ref><ref id="b5-ppa-6-887"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havlir</surname><given-names>DV</given-names></name><name><surname>Kendall</surname><given-names>MA</given-names></name><name><surname>Ive</surname><given-names>P</given-names></name><etal/></person-group><article-title>Timing of antiretroviral therapy for HIV-1 infection and tuberculosis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>16</issue><fpage>1482</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">22010914</pub-id></element-citation></ref><ref id="b6-ppa-6-887"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachega</surname><given-names>JB</given-names></name><name><surname>Chaisson</surname><given-names>RE</given-names></name><name><surname>Goliath</surname><given-names>R</given-names></name><etal/></person-group><article-title>Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>1273</fpage><lpage>1280</lpage><pub-id pub-id-type="pmid">20453627</pub-id></element-citation></ref><ref id="b7-ppa-6-887"><label>7</label><element-citation publication-type="webpage"><collab>Southern African HIV Clinicians Soceity</collab><article-title>Antiretroviral Therapy in Adults, January 2008</article-title><source>South Afr J HIV Med</source><year>2008</year><fpage>18</fpage><lpage>31</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hivhotline.uct.ac.za/sahivsoc_guideline_ADULT.pdf">http://www.hivhotline.uct.ac.za/sahivsoc_guideline_ADULT.pdf</ext-link></comment><date-in-citation>Accessed May 22, 2012</date-in-citation></element-citation></ref><ref id="b8-ppa-6-887"><label>8</label><element-citation publication-type="book"><collab>Republic of South Africa Department of Health</collab><source>National Tuberculosis Management Guidelines</source><publisher-name>South Africa Department of Health</publisher-name><year>2009</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx">http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx</ext-link></comment><date-in-citation>Accessed May 22, 2012</date-in-citation></element-citation></ref><ref id="b9-ppa-6-887"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schag</surname><given-names>CC</given-names></name><name><surname>Heinrich</surname><given-names>RL</given-names></name><name><surname>Ganz</surname><given-names>PA</given-names></name></person-group><article-title>Karnofsky performance status revisited: Reliability, validity, and guidelines</article-title><source>J Clin Oncology</source><year>1984</year><volume>2</volume><fpage>187</fpage><lpage>193</lpage></element-citation></ref><ref id="b10-ppa-6-887"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Lawn</surname><given-names>SD</given-names></name><name><surname>Scano</surname><given-names>F</given-names></name><etal/></person-group><collab>International Network for the Study of HIV-associated IRIS</collab><article-title>Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings</article-title><source>Lancet Infect Dis</source><year>2008</year><volume>8</volume><issue>8</issue><fpage>516</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">18652998</pub-id></element-citation></ref><ref id="b11-ppa-6-887"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddow</surname><given-names>LJ</given-names></name><name><surname>Colebunders</surname><given-names>R</given-names></name><name><surname>Meintjes</surname><given-names>G</given-names></name><etal/></person-group><collab>International Network for the Study of HIV-associated IRIS (INSHI)</collab><article-title>Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><issue>11</issue><fpage>791</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">21029993</pub-id></element-citation></ref><ref id="b12-ppa-6-887"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehloenya</surname><given-names>R</given-names></name><name><surname>Meintjes</surname><given-names>G</given-names></name></person-group><article-title>Dermatologic manifestations of the immune reconstitution inflammatory syndrome</article-title><source>Dermatol Clin</source><year>2006</year><volume>24</volume><fpage>549</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">17010783</pub-id></element-citation></ref><ref id="b13-ppa-6-887"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewing</surname><given-names>JA</given-names></name></person-group><article-title>Detecting alcoholism: The CAGE questionnaire</article-title><source>J Am Med Assoc</source><year>1984</year><volume>252</volume><fpage>1905</fpage><lpage>1906</lpage></element-citation></ref><ref id="b14-ppa-6-887"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ashkin</surname><given-names>D</given-names></name><name><surname>Hollender</surname><given-names>ES</given-names></name><name><surname>Pitchenik</surname><given-names>AE</given-names></name></person-group><article-title>Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">9655723</pub-id></element-citation></ref><ref id="b15-ppa-6-887"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eshun-Wilson</surname><given-names>I</given-names></name><name><surname>Havers</surname><given-names>F</given-names></name><name><surname>Nachega</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings</article-title><source>J Int Assoc Physicians AIDS Care (Chic)</source><year>2010</year><volume>9</volume><issue>2</issue><fpage>104</fpage><lpage>108</lpage><comment>Epub February 16, 2010</comment><pub-id pub-id-type="pmid">20160249</pub-id></element-citation></ref><ref id="b16-ppa-6-887"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepper</surname><given-names>DJ</given-names></name><name><surname>Marais</surname><given-names>S</given-names></name><name><surname>Maartens</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neurological manifestations of paradoxical tuberculsosis-associated immune reconstitution inflammatory syndrome: a case series</article-title><source>Clin Infec Dis</source><year>2009</year><volume>48</volume><fpage>e96</fpage><lpage>e107</lpage><pub-id pub-id-type="pmid">19405867</pub-id></element-citation></ref><ref id="b17-ppa-6-887"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>S</given-names></name><name><surname>Meinjtjes</surname><given-names>G</given-names></name></person-group><article-title>Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy</article-title><source>Expert Rev Anti Infect Ther</source><year>2011</year><volume>9</volume><issue>4</issue><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">21504399</pub-id></element-citation></ref><ref id="b18-ppa-6-887"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Mugavero</surname><given-names>MJ</given-names></name><name><surname>Amico</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel</article-title><source>Ann Intern Med</source><year>2012</year><volume>156</volume><fpage>817</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">22393036</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-ppa-6-887" position="float"><label>Table 1</label><caption><p>Patient clinical and demographic characteristics at enrollment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="left" valign="top" rowspan="1" colspan="1">IRIS<break/>n = 23</th><th align="left" valign="top" rowspan="1" colspan="1">No IRIS<break/>n = 251</th><th align="left" valign="top" rowspan="1" colspan="1">Total<break/>n = 274</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Median age in years (range)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (29&#x02013;44)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (30&#x02013;41)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (18&#x02013;74)</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Enrolled in DOT-ART arm of parent RCT, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (52%)</td><td align="left" valign="top" rowspan="1" colspan="1">125 (48%)</td><td align="left" valign="top" rowspan="1" colspan="1">137 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (57%)</td><td align="left" valign="top" rowspan="1" colspan="1">145 (58%)</td><td align="left" valign="top" rowspan="1" colspan="1">158 (58%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">WHO clinical stage, n (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;I&#x02013;III</td><td align="left" valign="top" rowspan="1" colspan="1">10 (43%)</td><td align="left" valign="top" rowspan="1" colspan="1">138 (55%)</td><td align="left" valign="top" rowspan="1" colspan="1">148 (54%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;IV</td><td align="left" valign="top" rowspan="1" colspan="1">13 (57%)</td><td align="left" valign="top" rowspan="1" colspan="1">113 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">126 (46%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol abuse (CAGE+), n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (22%)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR) CD4+ T-cell count (cells/&#x003bc;L)</td><td align="left" valign="top" rowspan="1" colspan="1">78 (37&#x02013;112)</td><td align="left" valign="top" rowspan="1" colspan="1">99 (45&#x02013;150)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (43&#x02013;148)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Type of NNRTI</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Efavirenz</td><td align="left" valign="top" rowspan="1" colspan="1">19 (83%)</td><td align="left" valign="top" rowspan="1" colspan="1">207 (83%)</td><td align="left" valign="top" rowspan="1" colspan="1">226 (83%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nevirapine</td><td align="left" valign="top" rowspan="1" colspan="1">4 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR) Log<sub>10</sub> HIV-1 RNA</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (4.5&#x02013;5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (4.6&#x02013;5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (4.6&#x02013;5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.94</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ppa-6-887"><p><bold>Abbreviations:</bold> IRIS, immune response inflammatory response; DOT-ART, directly observed antiviral therapy; RCT, randomized controlled trial; WHO, World Health Organization; CAGE+, Cut down, Annoyed by criticism, Guilty about drinking, Eye-opener drinks questionnaire; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; HIV, human immunodeficiency virus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ppa-6-887" position="float"><label>Table 2</label><caption><p>Univariate and multivariate factors associated with ART adherence below the median</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="left" valign="top" rowspan="1" colspan="1">Univariate RR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" valign="top" rowspan="1" colspan="1">Multivariate RR (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Age (years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003c;40</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;40</td><td align="left" valign="top" rowspan="1" colspan="1">1.15 (0.87&#x02013;1.51)</td><td align="left" valign="top" rowspan="1" colspan="1">0.34</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" valign="top" rowspan="1" colspan="1">1.02 (0.77&#x02013;1.34)</td><td align="left" valign="top" rowspan="1" colspan="1">0.90</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">WHO clinical stage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Stage I&#x02013;III</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Stage IV</td><td align="left" valign="top" rowspan="1" colspan="1">1.09 (0.82&#x02013;1.43)</td><td align="left" valign="top" rowspan="1" colspan="1">0.70</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Alcohol abuse (CAGE+)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.61 (1.24&#x02013;2.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.003</td><td align="left" valign="top" rowspan="1" colspan="1">1.51 (1.15&#x02013;1.99)</td><td align="left" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">IRIS event</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.76 (1.31&#x02013;2.34)</td><td align="left" valign="top" rowspan="1" colspan="1">0.007</td><td align="left" valign="top" rowspan="1" colspan="1">1.65 (1.22&#x02013;2.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">CD4+ T-cell count (cells/&#x003bc;L)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;100</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003c;100</td><td align="left" valign="top" rowspan="1" colspan="1">1.12 (0.85&#x02013;1.47)</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">0.90 (0.69&#x02013;1.18)</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Log<sub>10</sub> HIV-1 RNA (copies/mL)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003c;5.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;5.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.08 (0.83&#x02013;1.42)</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ppa-6-887"><p><bold>Abbreviations:</bold> RR, relative risk; CI, confidence interval; N/A, not applicable; CAGE+, Cut down, Annoyed by criticism, Guilty about drinking, Eye-opener drinks questionnaire; IRIS, immune reconstitution inflammatory syndrome; HIV, human immunodeficiency virus.</p></fn></table-wrap-foot></table-wrap></floats-group></article>